FDA reviews new interpretation of study on Avandia risks
06/05/2013 // West Palm Beach , Florida, US // JusticeNewsFlash // Justice News Flash // (press release)
Washington – The Food and Drug Administration is set to review a new interpretation of a study regarding the health risks linked to the diabetes drug Avandia. As reported by the Associated Press (AP), the FDA will reportedly weigh in on lifting safety restrictions in addition to other options for use of the drug.
The GlaxoSmithKline drug received a positive safety review from researchers from Duke University after years of debate regarding the purported associated heart attack risks. Due to the link between diabetes and a predisposition to heart problems, medical experts have long been divided on whether the drug increases heart attack risks or whether the increased risks for patients taking Avandia are linked to their disease.
The FDA restricted Avandia use in 2010. Glaxo reportedly paid $90 million last year in a settlement after being accused by 38 state governments of misrepresenting Avandia risks.
Justice News Flash delivers the latest in Washington legal news.
Address: 215 South Olive Suite 300 W. Palm Beach FL 33401